nodes	percent_of_prediction	percent_of_DWPC	metapath
Riluzole—CYP1A1—Progesterone—uterine cancer	0.162	0.257	CbGbCtD
Riluzole—ABCG2—Dactinomycin—uterine cancer	0.14	0.22	CbGbCtD
Riluzole—ABCG2—Carboplatin—uterine cancer	0.0938	0.148	CbGbCtD
Riluzole—ABCG2—Etoposide—uterine cancer	0.0787	0.124	CbGbCtD
Riluzole—CYP1A2—Progesterone—uterine cancer	0.0725	0.115	CbGbCtD
Riluzole—ABCG2—Doxorubicin—uterine cancer	0.0537	0.0848	CbGbCtD
Riluzole—CYP1A2—Etoposide—uterine cancer	0.0325	0.0513	CbGbCtD
Riluzole—SLC7A11—Transcriptional activation by NRF2—NFE2L2—uterine cancer	0.00293	0.139	CbGpPWpGaD
Riluzole—SLC7A11—smooth muscle tissue—uterine cancer	0.00221	0.11	CbGeAlD
Riluzole—SLC7A11—renal system—uterine cancer	0.00213	0.106	CbGeAlD
Riluzole—SLC7A11—female reproductive system—uterine cancer	0.00171	0.085	CbGeAlD
Riluzole—SLC7A11—female gonad—uterine cancer	0.00155	0.0774	CbGeAlD
Riluzole—CYP1A1—Benzo(a)pyrene metabolism—AKR1C1—uterine cancer	0.00117	0.0557	CbGpPWpGaD
Riluzole—ABCG2—myometrium—uterine cancer	0.000963	0.048	CbGeAlD
Riluzole—SCN5A—vagina—uterine cancer	0.000929	0.0463	CbGeAlD
Riluzole—CYP1A1—Benzo(a)pyrene metabolism—AKR1C3—uterine cancer	0.000903	0.0429	CbGpPWpGaD
Riluzole—SCN5A—Cardiac Progenitor Differentiation—INHBA—uterine cancer	0.000762	0.0362	CbGpPWpGaD
Riluzole—ABCG2—uterine cervix—uterine cancer	0.00075	0.0374	CbGeAlD
Riluzole—CYP1A1—epithelium—uterine cancer	0.000718	0.0358	CbGeAlD
Riluzole—ABCG2—decidua—uterine cancer	0.000714	0.0356	CbGeAlD
Riluzole—CYP1A1—uterine cervix—uterine cancer	0.000712	0.0355	CbGeAlD
Riluzole—ABCG2—endometrium—uterine cancer	0.000678	0.0338	CbGeAlD
Riluzole—CYP1A2—renal system—uterine cancer	0.000675	0.0336	CbGeAlD
Riluzole—CYP1A1—renal system—uterine cancer	0.000666	0.0332	CbGeAlD
Riluzole—ABCG2—mammalian vulva—uterine cancer	0.000656	0.0327	CbGeAlD
Riluzole—ABCG2—uterus—uterine cancer	0.000625	0.0311	CbGeAlD
Riluzole—CYP1A1—mammalian vulva—uterine cancer	0.000623	0.031	CbGeAlD
Riluzole—CYP1A1—uterus—uterine cancer	0.000593	0.0296	CbGeAlD
Riluzole—SLC7A11—Transcriptional activation by NRF2—PIK3CA—uterine cancer	0.000562	0.0267	CbGpPWpGaD
Riluzole—ABCG2—Fluoropyrimidine Activity—RRM2—uterine cancer	0.000546	0.0259	CbGpPWpGaD
Riluzole—CYP1A1—female reproductive system—uterine cancer	0.000533	0.0266	CbGeAlD
Riluzole—ABCG2—female gonad—uterine cancer	0.000511	0.0255	CbGeAlD
Riluzole—ABCG2—vagina—uterine cancer	0.000508	0.0253	CbGeAlD
Riluzole—CYP1A1—female gonad—uterine cancer	0.000485	0.0242	CbGeAlD
Riluzole—CYP1A1—vagina—uterine cancer	0.000482	0.024	CbGeAlD
Riluzole—SLC7A11—NRF2 pathway—NFE2L2—uterine cancer	0.000474	0.0225	CbGpPWpGaD
Riluzole—SLC7A11—NRF2 pathway—GPX3—uterine cancer	0.000452	0.0215	CbGpPWpGaD
Riluzole—CYP1A1—Oxidative Stress—NFE2L2—uterine cancer	0.000412	0.0196	CbGpPWpGaD
Riluzole—CYP1A1—Oxidative Stress—GPX3—uterine cancer	0.000393	0.0187	CbGpPWpGaD
Riluzole—CYP1A1—Estrogen Receptor Pathway—ESR1—uterine cancer	0.00035	0.0166	CbGpPWpGaD
Riluzole—SCN5A—Axon guidance—PLXNA3—uterine cancer	0.000341	0.0162	CbGpPWpGaD
Riluzole—ABCG2—lymph node—uterine cancer	0.000329	0.0164	CbGeAlD
Riluzole—CYP1A1—lymph node—uterine cancer	0.000312	0.0156	CbGeAlD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—NFE2L2—uterine cancer	0.000293	0.0139	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—NFE2L2—uterine cancer	0.000293	0.0139	CbGpPWpGaD
Riluzole—ABCG2—Fluoropyrimidine Activity—MTHFR—uterine cancer	0.000276	0.0131	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—PLXNA3—uterine cancer	0.000243	0.0115	CbGpPWpGaD
Riluzole—CYP1A1—Arachidonic acid metabolism—AKR1C3—uterine cancer	0.000229	0.0109	CbGpPWpGaD
Riluzole—SLC7A11—Transmembrane transport of small molecules—ABCC9—uterine cancer	0.000225	0.0107	CbGpPWpGaD
Riluzole—CYP1A2—Estrogen Receptor Pathway—ESR1—uterine cancer	0.000223	0.0106	CbGpPWpGaD
Riluzole—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	0.00021	0.00995	CbGpPWpGaD
Riluzole—SCN5A—SIDS Susceptibility Pathways—YWHAE—uterine cancer	0.000207	0.00983	CbGpPWpGaD
Riluzole—CYP1A1—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	0.000207	0.00982	CbGpPWpGaD
Riluzole—SCN5A—SIDS Susceptibility Pathways—ESR2—uterine cancer	0.000191	0.00907	CbGpPWpGaD
Riluzole—CYP1A1—Tryptophan metabolism—CYP19A1—uterine cancer	0.000191	0.00905	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—NFE2L2—uterine cancer	0.000187	0.00886	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—NFE2L2—uterine cancer	0.000187	0.00886	CbGpPWpGaD
Riluzole—ABCG2—HIF-1-alpha transcription factor network—SMAD3—uterine cancer	0.000173	0.0082	CbGpPWpGaD
Riluzole—CYP1A1—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	0.00017	0.00807	CbGpPWpGaD
Riluzole—CYP1A1—Metapathway biotransformation—AKR1B10—uterine cancer	0.00016	0.0076	CbGpPWpGaD
Riluzole—SLC7A11—Cell surface interactions at the vascular wall—NRAS—uterine cancer	0.000157	0.00746	CbGpPWpGaD
Riluzole—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	0.000154	0.00732	CbGpPWpGaD
Riluzole—CYP1A1—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	0.000152	0.00722	CbGpPWpGaD
Riluzole—CYP1A1—Metapathway biotransformation—AKR1B1—uterine cancer	0.000149	0.00706	CbGpPWpGaD
Riluzole—CYP1A2—Arachidonic acid metabolism—AKR1C3—uterine cancer	0.000146	0.00693	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—IRF1—uterine cancer	0.000146	0.00692	CbGpPWpGaD
Riluzole—ABCG2—HIF-2-alpha transcription factor network—EP300—uterine cancer	0.000143	0.00679	CbGpPWpGaD
Riluzole—Aspartate aminotransferase increased—Doxorubicin—uterine cancer	0.000142	0.000437	CcSEcCtD
Riluzole—Bronchitis—Epirubicin—uterine cancer	0.000142	0.000436	CcSEcCtD
Riluzole—Diarrhoea—Dactinomycin—uterine cancer	0.000142	0.000435	CcSEcCtD
Riluzole—Pancytopenia—Epirubicin—uterine cancer	0.00014	0.00043	CcSEcCtD
Riluzole—Hypotension—Etoposide—uterine cancer	0.00014	0.00043	CcSEcCtD
Riluzole—Gastritis—Doxorubicin—uterine cancer	0.00014	0.000429	CcSEcCtD
Riluzole—Muscular weakness—Doxorubicin—uterine cancer	0.000139	0.000428	CcSEcCtD
Riluzole—Alanine aminotransferase increased—Doxorubicin—uterine cancer	0.000139	0.000428	CcSEcCtD
Riluzole—Neutropenia—Epirubicin—uterine cancer	0.000138	0.000424	CcSEcCtD
Riluzole—Dysuria—Epirubicin—uterine cancer	0.000138	0.000424	CcSEcCtD
Riluzole—Abdominal distension—Doxorubicin—uterine cancer	0.000138	0.000422	CcSEcCtD
Riluzole—Dysphagia—Doxorubicin—uterine cancer	0.000137	0.000419	CcSEcCtD
Riluzole—Asthma—Doxorubicin—uterine cancer	0.000137	0.000419	CcSEcCtD
Riluzole—Influenza—Doxorubicin—uterine cancer	0.000137	0.000419	CcSEcCtD
Riluzole—Pollakiuria—Epirubicin—uterine cancer	0.000136	0.000419	CcSEcCtD
Riluzole—ABCG2—HIF-2-alpha transcription factor network—VEGFA—uterine cancer	0.000136	0.00643	CbGpPWpGaD
Riluzole—SLC7A11—Cell surface interactions at the vascular wall—KRAS—uterine cancer	0.000135	0.00642	CbGpPWpGaD
Riluzole—Photosensitivity reaction—Epirubicin—uterine cancer	0.000135	0.000414	CcSEcCtD
Riluzole—Paraesthesia—Etoposide—uterine cancer	0.000135	0.000413	CcSEcCtD
Riluzole—Weight increased—Epirubicin—uterine cancer	0.000134	0.000413	CcSEcCtD
Riluzole—Pancreatitis—Doxorubicin—uterine cancer	0.000134	0.000411	CcSEcCtD
Riluzole—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	0.000134	0.00634	CbGpPWpGaD
Riluzole—Weight decreased—Epirubicin—uterine cancer	0.000134	0.00041	CcSEcCtD
Riluzole—Dyspnoea—Etoposide—uterine cancer	0.000134	0.00041	CcSEcCtD
Riluzole—Somnolence—Etoposide—uterine cancer	0.000133	0.000409	CcSEcCtD
Riluzole—Angina pectoris—Doxorubicin—uterine cancer	0.000133	0.000409	CcSEcCtD
Riluzole—Pneumonia—Epirubicin—uterine cancer	0.000132	0.000407	CcSEcCtD
Riluzole—CYP1A2—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	0.000132	0.00626	CbGpPWpGaD
Riluzole—Infestation—Epirubicin—uterine cancer	0.000132	0.000404	CcSEcCtD
Riluzole—Infestation NOS—Epirubicin—uterine cancer	0.000132	0.000404	CcSEcCtD
Riluzole—Vomiting—Dactinomycin—uterine cancer	0.000132	0.000404	CcSEcCtD
Riluzole—Bronchitis—Doxorubicin—uterine cancer	0.000131	0.000403	CcSEcCtD
Riluzole—Rash—Dactinomycin—uterine cancer	0.000131	0.000401	CcSEcCtD
Riluzole—Decreased appetite—Etoposide—uterine cancer	0.00013	0.0004	CcSEcCtD
Riluzole—Pancytopenia—Doxorubicin—uterine cancer	0.00013	0.000398	CcSEcCtD
Riluzole—Gastrointestinal disorder—Etoposide—uterine cancer	0.000129	0.000397	CcSEcCtD
Riluzole—Fatigue—Etoposide—uterine cancer	0.000129	0.000396	CcSEcCtD
Riluzole—Neuropathy peripheral—Epirubicin—uterine cancer	0.000129	0.000396	CcSEcCtD
Riluzole—Stomatitis—Epirubicin—uterine cancer	0.000128	0.000394	CcSEcCtD
Riluzole—Jaundice—Epirubicin—uterine cancer	0.000128	0.000394	CcSEcCtD
Riluzole—Pain—Etoposide—uterine cancer	0.000128	0.000393	CcSEcCtD
Riluzole—Constipation—Etoposide—uterine cancer	0.000128	0.000393	CcSEcCtD
Riluzole—Urinary tract infection—Epirubicin—uterine cancer	0.000128	0.000393	CcSEcCtD
Riluzole—SCN5A—Developmental Biology—HNF1B—uterine cancer	0.000128	0.00607	CbGpPWpGaD
Riluzole—Neutropenia—Doxorubicin—uterine cancer	0.000128	0.000392	CcSEcCtD
Riluzole—Dysuria—Doxorubicin—uterine cancer	0.000128	0.000392	CcSEcCtD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—ESR1—uterine cancer	0.000127	0.00605	CbGpPWpGaD
Riluzole—Sweating—Epirubicin—uterine cancer	0.000126	0.000387	CcSEcCtD
Riluzole—Pollakiuria—Doxorubicin—uterine cancer	0.000126	0.000387	CcSEcCtD
Riluzole—Haematuria—Epirubicin—uterine cancer	0.000126	0.000385	CcSEcCtD
Riluzole—CYP1A1—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	0.000125	0.00593	CbGpPWpGaD
Riluzole—Photosensitivity reaction—Doxorubicin—uterine cancer	0.000125	0.000383	CcSEcCtD
Riluzole—Hepatobiliary disease—Epirubicin—uterine cancer	0.000125	0.000382	CcSEcCtD
Riluzole—Weight increased—Doxorubicin—uterine cancer	0.000124	0.000382	CcSEcCtD
Riluzole—SLC7A11—Cell surface interactions at the vascular wall—PIK3CA—uterine cancer	0.000124	0.0059	CbGpPWpGaD
Riluzole—Epistaxis—Epirubicin—uterine cancer	0.000124	0.000381	CcSEcCtD
Riluzole—Weight decreased—Doxorubicin—uterine cancer	0.000124	0.000379	CcSEcCtD
Riluzole—Sinusitis—Epirubicin—uterine cancer	0.000124	0.000379	CcSEcCtD
Riluzole—Feeling abnormal—Etoposide—uterine cancer	0.000123	0.000379	CcSEcCtD
Riluzole—Nausea—Dactinomycin—uterine cancer	0.000123	0.000377	CcSEcCtD
Riluzole—Agranulocytosis—Epirubicin—uterine cancer	0.000123	0.000377	CcSEcCtD
Riluzole—Pneumonia—Doxorubicin—uterine cancer	0.000123	0.000376	CcSEcCtD
Riluzole—Gastrointestinal pain—Etoposide—uterine cancer	0.000123	0.000376	CcSEcCtD
Riluzole—Infestation—Doxorubicin—uterine cancer	0.000122	0.000374	CcSEcCtD
Riluzole—Infestation NOS—Doxorubicin—uterine cancer	0.000122	0.000374	CcSEcCtD
Riluzole—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—uterine cancer	0.000122	0.00577	CbGpPWpGaD
Riluzole—CYP1A2—Tryptophan metabolism—CYP19A1—uterine cancer	0.000122	0.00577	CbGpPWpGaD
Riluzole—Bradycardia—Epirubicin—uterine cancer	0.00012	0.000369	CcSEcCtD
Riluzole—Neuropathy peripheral—Doxorubicin—uterine cancer	0.000119	0.000367	CcSEcCtD
Riluzole—Urticaria—Etoposide—uterine cancer	0.000119	0.000365	CcSEcCtD
Riluzole—Haemoglobin—Epirubicin—uterine cancer	0.000119	0.000365	CcSEcCtD
Riluzole—Jaundice—Doxorubicin—uterine cancer	0.000119	0.000365	CcSEcCtD
Riluzole—Stomatitis—Doxorubicin—uterine cancer	0.000119	0.000365	CcSEcCtD
Riluzole—Rhinitis—Epirubicin—uterine cancer	0.000118	0.000364	CcSEcCtD
Riluzole—Abdominal pain—Etoposide—uterine cancer	0.000118	0.000364	CcSEcCtD
Riluzole—Body temperature increased—Etoposide—uterine cancer	0.000118	0.000364	CcSEcCtD
Riluzole—Urinary tract infection—Doxorubicin—uterine cancer	0.000118	0.000363	CcSEcCtD
Riluzole—Hepatitis—Epirubicin—uterine cancer	0.000118	0.000363	CcSEcCtD
Riluzole—Haemorrhage—Epirubicin—uterine cancer	0.000118	0.000363	CcSEcCtD
Riluzole—Hypoaesthesia—Epirubicin—uterine cancer	0.000118	0.000361	CcSEcCtD
Riluzole—Pharyngitis—Epirubicin—uterine cancer	0.000117	0.00036	CcSEcCtD
Riluzole—Sweating—Doxorubicin—uterine cancer	0.000117	0.000359	CcSEcCtD
Riluzole—Urinary tract disorder—Epirubicin—uterine cancer	0.000117	0.000358	CcSEcCtD
Riluzole—Oedema peripheral—Epirubicin—uterine cancer	0.000116	0.000357	CcSEcCtD
Riluzole—Haematuria—Doxorubicin—uterine cancer	0.000116	0.000357	CcSEcCtD
Riluzole—Connective tissue disorder—Epirubicin—uterine cancer	0.000116	0.000357	CcSEcCtD
Riluzole—Urethral disorder—Epirubicin—uterine cancer	0.000116	0.000356	CcSEcCtD
Riluzole—Hepatobiliary disease—Doxorubicin—uterine cancer	0.000115	0.000354	CcSEcCtD
Riluzole—SLC7A11—Cell surface interactions at the vascular wall—HRAS—uterine cancer	0.000115	0.00546	CbGpPWpGaD
Riluzole—Epistaxis—Doxorubicin—uterine cancer	0.000115	0.000353	CcSEcCtD
Riluzole—Sinusitis—Doxorubicin—uterine cancer	0.000114	0.000351	CcSEcCtD
Riluzole—Agranulocytosis—Doxorubicin—uterine cancer	0.000114	0.000349	CcSEcCtD
Riluzole—Erythema multiforme—Epirubicin—uterine cancer	0.000112	0.000343	CcSEcCtD
Riluzole—Bradycardia—Doxorubicin—uterine cancer	0.000111	0.000342	CcSEcCtD
Riluzole—Eye disorder—Epirubicin—uterine cancer	0.00011	0.000339	CcSEcCtD
Riluzole—Hypersensitivity—Etoposide—uterine cancer	0.00011	0.000339	CcSEcCtD
Riluzole—Haemoglobin—Doxorubicin—uterine cancer	0.00011	0.000337	CcSEcCtD
Riluzole—Cardiac disorder—Epirubicin—uterine cancer	0.00011	0.000337	CcSEcCtD
Riluzole—Rhinitis—Doxorubicin—uterine cancer	0.00011	0.000337	CcSEcCtD
Riluzole—Haemorrhage—Doxorubicin—uterine cancer	0.000109	0.000336	CcSEcCtD
Riluzole—Hepatitis—Doxorubicin—uterine cancer	0.000109	0.000336	CcSEcCtD
Riluzole—CYP1A1—Metapathway biotransformation—AKR1C1—uterine cancer	0.000109	0.00518	CbGpPWpGaD
Riluzole—Hypoaesthesia—Doxorubicin—uterine cancer	0.000109	0.000334	CcSEcCtD
Riluzole—Pharyngitis—Doxorubicin—uterine cancer	0.000109	0.000333	CcSEcCtD
Riluzole—CYP1A2—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	0.000108	0.00514	CbGpPWpGaD
Riluzole—Urinary tract disorder—Doxorubicin—uterine cancer	0.000108	0.000332	CcSEcCtD
Riluzole—Oedema peripheral—Doxorubicin—uterine cancer	0.000108	0.000331	CcSEcCtD
Riluzole—Asthenia—Etoposide—uterine cancer	0.000107	0.00033	CcSEcCtD
Riluzole—Connective tissue disorder—Doxorubicin—uterine cancer	0.000107	0.00033	CcSEcCtD
Riluzole—Angiopathy—Epirubicin—uterine cancer	0.000107	0.000329	CcSEcCtD
Riluzole—Urethral disorder—Doxorubicin—uterine cancer	0.000107	0.000329	CcSEcCtD
Riluzole—Immune system disorder—Epirubicin—uterine cancer	0.000107	0.000328	CcSEcCtD
Riluzole—Mediastinal disorder—Epirubicin—uterine cancer	0.000107	0.000327	CcSEcCtD
Riluzole—Chills—Epirubicin—uterine cancer	0.000106	0.000326	CcSEcCtD
Riluzole—Pruritus—Etoposide—uterine cancer	0.000106	0.000325	CcSEcCtD
Riluzole—Arrhythmia—Epirubicin—uterine cancer	0.000106	0.000324	CcSEcCtD
Riluzole—ABCG2—Fluoropyrimidine Activity—TP53—uterine cancer	0.000105	0.00498	CbGpPWpGaD
Riluzole—Alopecia—Epirubicin—uterine cancer	0.000104	0.000321	CcSEcCtD
Riluzole—Mental disorder—Epirubicin—uterine cancer	0.000104	0.000318	CcSEcCtD
Riluzole—Erythema multiforme—Doxorubicin—uterine cancer	0.000103	0.000317	CcSEcCtD
Riluzole—Malnutrition—Epirubicin—uterine cancer	0.000103	0.000316	CcSEcCtD
Riluzole—Diarrhoea—Etoposide—uterine cancer	0.000102	0.000315	CcSEcCtD
Riluzole—Eye disorder—Doxorubicin—uterine cancer	0.000102	0.000314	CcSEcCtD
Riluzole—CYP1A2—Metapathway biotransformation—AKR1B10—uterine cancer	0.000102	0.00484	CbGpPWpGaD
Riluzole—Cardiac disorder—Doxorubicin—uterine cancer	0.000101	0.000312	CcSEcCtD
Riluzole—Flatulence—Epirubicin—uterine cancer	0.000101	0.000311	CcSEcCtD
Riluzole—Tension—Epirubicin—uterine cancer	0.000101	0.00031	CcSEcCtD
Riluzole—Dysgeusia—Epirubicin—uterine cancer	0.000101	0.000309	CcSEcCtD
Riluzole—Nervousness—Epirubicin—uterine cancer	9.99e-05	0.000307	CcSEcCtD
Riluzole—Back pain—Epirubicin—uterine cancer	9.95e-05	0.000306	CcSEcCtD
Riluzole—Angiopathy—Doxorubicin—uterine cancer	9.92e-05	0.000305	CcSEcCtD
Riluzole—Dizziness—Etoposide—uterine cancer	9.91e-05	0.000304	CcSEcCtD
Riluzole—Muscle spasms—Epirubicin—uterine cancer	9.89e-05	0.000304	CcSEcCtD
Riluzole—Immune system disorder—Doxorubicin—uterine cancer	9.88e-05	0.000303	CcSEcCtD
Riluzole—Mediastinal disorder—Doxorubicin—uterine cancer	9.86e-05	0.000303	CcSEcCtD
Riluzole—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	9.84e-05	0.00467	CbGpPWpGaD
Riluzole—Chills—Doxorubicin—uterine cancer	9.81e-05	0.000301	CcSEcCtD
Riluzole—Arrhythmia—Doxorubicin—uterine cancer	9.77e-05	0.0003	CcSEcCtD
Riluzole—CYP1A2—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	9.71e-05	0.00461	CbGpPWpGaD
Riluzole—Alopecia—Doxorubicin—uterine cancer	9.66e-05	0.000297	CcSEcCtD
Riluzole—CYP1A1—Metapathway biotransformation—GPX3—uterine cancer	9.59e-05	0.00455	CbGpPWpGaD
Riluzole—Mental disorder—Doxorubicin—uterine cancer	9.58e-05	0.000294	CcSEcCtD
Riluzole—Ill-defined disorder—Epirubicin—uterine cancer	9.55e-05	0.000293	CcSEcCtD
Riluzole—Vomiting—Etoposide—uterine cancer	9.52e-05	0.000292	CcSEcCtD
Riluzole—Malnutrition—Doxorubicin—uterine cancer	9.52e-05	0.000292	CcSEcCtD
Riluzole—Anaemia—Epirubicin—uterine cancer	9.51e-05	0.000292	CcSEcCtD
Riluzole—CYP1A2—Metapathway biotransformation—AKR1B1—uterine cancer	9.49e-05	0.0045	CbGpPWpGaD
Riluzole—Agitation—Epirubicin—uterine cancer	9.46e-05	0.00029	CcSEcCtD
Riluzole—Rash—Etoposide—uterine cancer	9.45e-05	0.00029	CcSEcCtD
Riluzole—Dermatitis—Etoposide—uterine cancer	9.44e-05	0.00029	CcSEcCtD
Riluzole—Headache—Etoposide—uterine cancer	9.38e-05	0.000288	CcSEcCtD
Riluzole—Flatulence—Doxorubicin—uterine cancer	9.38e-05	0.000288	CcSEcCtD
Riluzole—Tension—Doxorubicin—uterine cancer	9.34e-05	0.000287	CcSEcCtD
Riluzole—Dysgeusia—Doxorubicin—uterine cancer	9.32e-05	0.000286	CcSEcCtD
Riluzole—Malaise—Epirubicin—uterine cancer	9.28e-05	0.000285	CcSEcCtD
Riluzole—Nervousness—Doxorubicin—uterine cancer	9.25e-05	0.000284	CcSEcCtD
Riluzole—Vertigo—Epirubicin—uterine cancer	9.24e-05	0.000284	CcSEcCtD
Riluzole—Syncope—Epirubicin—uterine cancer	9.23e-05	0.000283	CcSEcCtD
Riluzole—Leukopenia—Epirubicin—uterine cancer	9.21e-05	0.000283	CcSEcCtD
Riluzole—Back pain—Doxorubicin—uterine cancer	9.21e-05	0.000283	CcSEcCtD
Riluzole—Muscle spasms—Doxorubicin—uterine cancer	9.15e-05	0.000281	CcSEcCtD
Riluzole—Palpitations—Epirubicin—uterine cancer	9.09e-05	0.000279	CcSEcCtD
Riluzole—Loss of consciousness—Epirubicin—uterine cancer	9.04e-05	0.000278	CcSEcCtD
Riluzole—CYP1A1—Biological oxidations—CYP11A1—uterine cancer	9.03e-05	0.00428	CbGpPWpGaD
Riluzole—Cough—Epirubicin—uterine cancer	8.98e-05	0.000276	CcSEcCtD
Riluzole—Convulsion—Epirubicin—uterine cancer	8.91e-05	0.000274	CcSEcCtD
Riluzole—CYP1A1—Metapathway biotransformation—CYP11A1—uterine cancer	8.9e-05	0.00423	CbGpPWpGaD
Riluzole—Nausea—Etoposide—uterine cancer	8.9e-05	0.000273	CcSEcCtD
Riluzole—Hypertension—Epirubicin—uterine cancer	8.88e-05	0.000273	CcSEcCtD
Riluzole—Ill-defined disorder—Doxorubicin—uterine cancer	8.83e-05	0.000271	CcSEcCtD
Riluzole—Anaemia—Doxorubicin—uterine cancer	8.8e-05	0.00027	CcSEcCtD
Riluzole—Myalgia—Epirubicin—uterine cancer	8.76e-05	0.000269	CcSEcCtD
Riluzole—Arthralgia—Epirubicin—uterine cancer	8.76e-05	0.000269	CcSEcCtD
Riluzole—Chest pain—Epirubicin—uterine cancer	8.76e-05	0.000269	CcSEcCtD
Riluzole—Agitation—Doxorubicin—uterine cancer	8.75e-05	0.000269	CcSEcCtD
Riluzole—Anxiety—Epirubicin—uterine cancer	8.73e-05	0.000268	CcSEcCtD
Riluzole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	8.7e-05	0.000267	CcSEcCtD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—CDKN1B—uterine cancer	8.66e-05	0.00411	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—CDKN1B—uterine cancer	8.66e-05	0.00411	CbGpPWpGaD
Riluzole—Discomfort—Epirubicin—uterine cancer	8.65e-05	0.000266	CcSEcCtD
Riluzole—Malaise—Doxorubicin—uterine cancer	8.59e-05	0.000264	CcSEcCtD
Riluzole—Dry mouth—Epirubicin—uterine cancer	8.57e-05	0.000263	CcSEcCtD
Riluzole—Vertigo—Doxorubicin—uterine cancer	8.55e-05	0.000263	CcSEcCtD
Riluzole—Syncope—Doxorubicin—uterine cancer	8.54e-05	0.000262	CcSEcCtD
Riluzole—Leukopenia—Doxorubicin—uterine cancer	8.52e-05	0.000262	CcSEcCtD
Riluzole—Confusional state—Epirubicin—uterine cancer	8.47e-05	0.00026	CcSEcCtD
Riluzole—ABCG2—HIF-1-alpha transcription factor network—EP300—uterine cancer	8.42e-05	0.004	CbGpPWpGaD
Riluzole—Palpitations—Doxorubicin—uterine cancer	8.41e-05	0.000258	CcSEcCtD
Riluzole—CYP1A1—Metapathway biotransformation—AKR1C3—uterine cancer	8.41e-05	0.00399	CbGpPWpGaD
Riluzole—Anaphylactic shock—Epirubicin—uterine cancer	8.4e-05	0.000258	CcSEcCtD
Riluzole—Oedema—Epirubicin—uterine cancer	8.4e-05	0.000258	CcSEcCtD
Riluzole—Loss of consciousness—Doxorubicin—uterine cancer	8.37e-05	0.000257	CcSEcCtD
Riluzole—Infection—Epirubicin—uterine cancer	8.34e-05	0.000256	CcSEcCtD
Riluzole—Cough—Doxorubicin—uterine cancer	8.31e-05	0.000255	CcSEcCtD
Riluzole—Shock—Epirubicin—uterine cancer	8.26e-05	0.000254	CcSEcCtD
Riluzole—Convulsion—Doxorubicin—uterine cancer	8.25e-05	0.000253	CcSEcCtD
Riluzole—Nervous system disorder—Epirubicin—uterine cancer	8.24e-05	0.000253	CcSEcCtD
Riluzole—Thrombocytopenia—Epirubicin—uterine cancer	8.22e-05	0.000252	CcSEcCtD
Riluzole—Hypertension—Doxorubicin—uterine cancer	8.22e-05	0.000252	CcSEcCtD
Riluzole—Tachycardia—Epirubicin—uterine cancer	8.2e-05	0.000252	CcSEcCtD
Riluzole—Skin disorder—Epirubicin—uterine cancer	8.16e-05	0.00025	CcSEcCtD
Riluzole—ABCG2—Transmembrane transport of small molecules—ABCC9—uterine cancer	8.14e-05	0.00386	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—uterine cancer	8.13e-05	0.00386	CbGpPWpGaD
Riluzole—Hyperhidrosis—Epirubicin—uterine cancer	8.12e-05	0.000249	CcSEcCtD
Riluzole—Arthralgia—Doxorubicin—uterine cancer	8.11e-05	0.000249	CcSEcCtD
Riluzole—Chest pain—Doxorubicin—uterine cancer	8.11e-05	0.000249	CcSEcCtD
Riluzole—Myalgia—Doxorubicin—uterine cancer	8.11e-05	0.000249	CcSEcCtD
Riluzole—Anxiety—Doxorubicin—uterine cancer	8.08e-05	0.000248	CcSEcCtD
Riluzole—SCN5A—SIDS Susceptibility Pathways—CXCL8—uterine cancer	8.07e-05	0.00383	CbGpPWpGaD
Riluzole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	8.05e-05	0.000247	CcSEcCtD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	8.01e-05	0.0038	CbGpPWpGaD
Riluzole—Discomfort—Doxorubicin—uterine cancer	8.01e-05	0.000246	CcSEcCtD
Riluzole—Anorexia—Epirubicin—uterine cancer	8e-05	0.000246	CcSEcCtD
Riluzole—CYP1A2—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	7.97e-05	0.00378	CbGpPWpGaD
Riluzole—ABCG2—HIF-1-alpha transcription factor network—VEGFA—uterine cancer	7.97e-05	0.00378	CbGpPWpGaD
Riluzole—Dry mouth—Doxorubicin—uterine cancer	7.93e-05	0.000243	CcSEcCtD
Riluzole—Hypotension—Epirubicin—uterine cancer	7.85e-05	0.000241	CcSEcCtD
Riluzole—Confusional state—Doxorubicin—uterine cancer	7.83e-05	0.00024	CcSEcCtD
Riluzole—Oedema—Doxorubicin—uterine cancer	7.77e-05	0.000239	CcSEcCtD
Riluzole—Anaphylactic shock—Doxorubicin—uterine cancer	7.77e-05	0.000239	CcSEcCtD
Riluzole—Infection—Doxorubicin—uterine cancer	7.72e-05	0.000237	CcSEcCtD
Riluzole—Musculoskeletal discomfort—Epirubicin—uterine cancer	7.65e-05	0.000235	CcSEcCtD
Riluzole—Shock—Doxorubicin—uterine cancer	7.64e-05	0.000235	CcSEcCtD
Riluzole—Nervous system disorder—Doxorubicin—uterine cancer	7.62e-05	0.000234	CcSEcCtD
Riluzole—Thrombocytopenia—Doxorubicin—uterine cancer	7.61e-05	0.000234	CcSEcCtD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—EP300—uterine cancer	7.61e-05	0.00361	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EP300—uterine cancer	7.61e-05	0.00361	CbGpPWpGaD
Riluzole—Insomnia—Epirubicin—uterine cancer	7.6e-05	0.000233	CcSEcCtD
Riluzole—Tachycardia—Doxorubicin—uterine cancer	7.58e-05	0.000233	CcSEcCtD
Riluzole—Skin disorder—Doxorubicin—uterine cancer	7.55e-05	0.000232	CcSEcCtD
Riluzole—Paraesthesia—Epirubicin—uterine cancer	7.54e-05	0.000231	CcSEcCtD
Riluzole—Hyperhidrosis—Doxorubicin—uterine cancer	7.51e-05	0.000231	CcSEcCtD
Riluzole—Dyspnoea—Epirubicin—uterine cancer	7.49e-05	0.00023	CcSEcCtD
Riluzole—Somnolence—Epirubicin—uterine cancer	7.47e-05	0.000229	CcSEcCtD
Riluzole—SCN5A—SIDS Susceptibility Pathways—CTNNB1—uterine cancer	7.45e-05	0.00353	CbGpPWpGaD
Riluzole—Anorexia—Doxorubicin—uterine cancer	7.41e-05	0.000227	CcSEcCtD
Riluzole—Dyspepsia—Epirubicin—uterine cancer	7.39e-05	0.000227	CcSEcCtD
Riluzole—Decreased appetite—Epirubicin—uterine cancer	7.3e-05	0.000224	CcSEcCtD
Riluzole—Hypotension—Doxorubicin—uterine cancer	7.26e-05	0.000223	CcSEcCtD
Riluzole—Gastrointestinal disorder—Epirubicin—uterine cancer	7.25e-05	0.000223	CcSEcCtD
Riluzole—Fatigue—Epirubicin—uterine cancer	7.24e-05	0.000222	CcSEcCtD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—uterine cancer	7.2e-05	0.00342	CbGpPWpGaD
Riluzole—Pain—Epirubicin—uterine cancer	7.18e-05	0.00022	CcSEcCtD
Riluzole—Constipation—Epirubicin—uterine cancer	7.18e-05	0.00022	CcSEcCtD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—NRAS—uterine cancer	7.12e-05	0.00338	CbGpPWpGaD
Riluzole—Musculoskeletal discomfort—Doxorubicin—uterine cancer	7.08e-05	0.000217	CcSEcCtD
Riluzole—Insomnia—Doxorubicin—uterine cancer	7.03e-05	0.000216	CcSEcCtD
Riluzole—Paraesthesia—Doxorubicin—uterine cancer	6.98e-05	0.000214	CcSEcCtD
Riluzole—CYP1A2—Metapathway biotransformation—AKR1C1—uterine cancer	6.96e-05	0.00331	CbGpPWpGaD
Riluzole—Dyspnoea—Doxorubicin—uterine cancer	6.93e-05	0.000213	CcSEcCtD
Riluzole—SCN5A—SIDS Susceptibility Pathways—EP300—uterine cancer	6.92e-05	0.00328	CbGpPWpGaD
Riluzole—Feeling abnormal—Epirubicin—uterine cancer	6.92e-05	0.000212	CcSEcCtD
Riluzole—Somnolence—Doxorubicin—uterine cancer	6.91e-05	0.000212	CcSEcCtD
Riluzole—Gastrointestinal pain—Epirubicin—uterine cancer	6.87e-05	0.000211	CcSEcCtD
Riluzole—Dyspepsia—Doxorubicin—uterine cancer	6.84e-05	0.00021	CcSEcCtD
Riluzole—Decreased appetite—Doxorubicin—uterine cancer	6.75e-05	0.000207	CcSEcCtD
Riluzole—Gastrointestinal disorder—Doxorubicin—uterine cancer	6.71e-05	0.000206	CcSEcCtD
Riluzole—Fatigue—Doxorubicin—uterine cancer	6.7e-05	0.000206	CcSEcCtD
Riluzole—Urticaria—Epirubicin—uterine cancer	6.67e-05	0.000205	CcSEcCtD
Riluzole—Pain—Doxorubicin—uterine cancer	6.64e-05	0.000204	CcSEcCtD
Riluzole—Constipation—Doxorubicin—uterine cancer	6.64e-05	0.000204	CcSEcCtD
Riluzole—CYP1A1—Biological oxidations—CYP19A1—uterine cancer	6.64e-05	0.00315	CbGpPWpGaD
Riluzole—Body temperature increased—Epirubicin—uterine cancer	6.64e-05	0.000204	CcSEcCtD
Riluzole—Abdominal pain—Epirubicin—uterine cancer	6.64e-05	0.000204	CcSEcCtD
Riluzole—SCN5A—SIDS Susceptibility Pathways—VEGFA—uterine cancer	6.55e-05	0.00311	CbGpPWpGaD
Riluzole—CYP1A1—Metapathway biotransformation—CYP19A1—uterine cancer	6.55e-05	0.00311	CbGpPWpGaD
Riluzole—SCN5A—Axon guidance—MET—uterine cancer	6.49e-05	0.00308	CbGpPWpGaD
Riluzole—Feeling abnormal—Doxorubicin—uterine cancer	6.4e-05	0.000197	CcSEcCtD
Riluzole—Gastrointestinal pain—Doxorubicin—uterine cancer	6.35e-05	0.000195	CcSEcCtD
Riluzole—Hypersensitivity—Epirubicin—uterine cancer	6.19e-05	0.00019	CcSEcCtD
Riluzole—Urticaria—Doxorubicin—uterine cancer	6.17e-05	0.000189	CcSEcCtD
Riluzole—Abdominal pain—Doxorubicin—uterine cancer	6.14e-05	0.000189	CcSEcCtD
Riluzole—Body temperature increased—Doxorubicin—uterine cancer	6.14e-05	0.000189	CcSEcCtD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—KRAS—uterine cancer	6.12e-05	0.00291	CbGpPWpGaD
Riluzole—CYP1A2—Metapathway biotransformation—GPX3—uterine cancer	6.11e-05	0.0029	CbGpPWpGaD
Riluzole—Asthenia—Epirubicin—uterine cancer	6.02e-05	0.000185	CcSEcCtD
Riluzole—Pruritus—Epirubicin—uterine cancer	5.94e-05	0.000182	CcSEcCtD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	5.79e-05	0.00275	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—STAR—uterine cancer	5.79e-05	0.00275	CbGpPWpGaD
Riluzole—CYP1A2—Biological oxidations—CYP11A1—uterine cancer	5.76e-05	0.00273	CbGpPWpGaD
Riluzole—Diarrhoea—Epirubicin—uterine cancer	5.75e-05	0.000176	CcSEcCtD
Riluzole—Hypersensitivity—Doxorubicin—uterine cancer	5.72e-05	0.000176	CcSEcCtD
Riluzole—CYP1A2—Metapathway biotransformation—CYP11A1—uterine cancer	5.68e-05	0.00269	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—SMAD3—uterine cancer	5.65e-05	0.00268	CbGpPWpGaD
Riluzole—Asthenia—Doxorubicin—uterine cancer	5.57e-05	0.000171	CcSEcCtD
Riluzole—Dizziness—Epirubicin—uterine cancer	5.55e-05	0.00017	CcSEcCtD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—uterine cancer	5.52e-05	0.00262	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—uterine cancer	5.52e-05	0.00262	CbGpPWpGaD
Riluzole—Pruritus—Doxorubicin—uterine cancer	5.5e-05	0.000169	CcSEcCtD
Riluzole—CYP1A2—Metapathway biotransformation—AKR1C3—uterine cancer	5.36e-05	0.00254	CbGpPWpGaD
Riluzole—Vomiting—Epirubicin—uterine cancer	5.34e-05	0.000164	CcSEcCtD
Riluzole—Diarrhoea—Doxorubicin—uterine cancer	5.32e-05	0.000163	CcSEcCtD
Riluzole—Rash—Epirubicin—uterine cancer	5.29e-05	0.000163	CcSEcCtD
Riluzole—Dermatitis—Epirubicin—uterine cancer	5.29e-05	0.000162	CcSEcCtD
Riluzole—ABCG2—Metabolism—NDUFB11—uterine cancer	5.27e-05	0.0025	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—SRD5A2—uterine cancer	5.27e-05	0.0025	CbGpPWpGaD
Riluzole—Headache—Epirubicin—uterine cancer	5.26e-05	0.000161	CcSEcCtD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—uterine cancer	5.21e-05	0.00247	CbGpPWpGaD
Riluzole—Dizziness—Doxorubicin—uterine cancer	5.14e-05	0.000158	CcSEcCtD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	5.11e-05	0.00243	CbGpPWpGaD
Riluzole—ABCG2—HIF-1-alpha transcription factor network—AKT1—uterine cancer	5.09e-05	0.00241	CbGpPWpGaD
Riluzole—Nausea—Epirubicin—uterine cancer	4.99e-05	0.000153	CcSEcCtD
Riluzole—Vomiting—Doxorubicin—uterine cancer	4.94e-05	0.000152	CcSEcCtD
Riluzole—Rash—Doxorubicin—uterine cancer	4.9e-05	0.00015	CcSEcCtD
Riluzole—Dermatitis—Doxorubicin—uterine cancer	4.89e-05	0.00015	CcSEcCtD
Riluzole—Headache—Doxorubicin—uterine cancer	4.87e-05	0.000149	CcSEcCtD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—uterine cancer	4.85e-05	0.0023	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—EP300—uterine cancer	4.85e-05	0.0023	CbGpPWpGaD
Riluzole—SCN5A—Axon guidance—ERBB2—uterine cancer	4.74e-05	0.00225	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—MET—uterine cancer	4.63e-05	0.0022	CbGpPWpGaD
Riluzole—Nausea—Doxorubicin—uterine cancer	4.62e-05	0.000142	CcSEcCtD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—uterine cancer	4.59e-05	0.00218	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—EP300—uterine cancer	4.56e-05	0.00216	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—uterine cancer	4.54e-05	0.00215	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—VEGFA—uterine cancer	4.32e-05	0.00205	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—NRAS—uterine cancer	4.26e-05	0.00202	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	4.25e-05	0.00202	CbGpPWpGaD
Riluzole—CYP1A2—Biological oxidations—CYP19A1—uterine cancer	4.24e-05	0.00201	CbGpPWpGaD
Riluzole—CYP1A2—Metapathway biotransformation—CYP19A1—uterine cancer	4.18e-05	0.00198	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—uterine cancer	3.91e-05	0.00185	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—STAR—uterine cancer	3.81e-05	0.00181	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—AKR1B1—uterine cancer	3.81e-05	0.00181	CbGpPWpGaD
Riluzole—CYP1A1—PPARA activates gene expression—EP300—uterine cancer	3.79e-05	0.0018	CbGpPWpGaD
Riluzole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—uterine cancer	3.71e-05	0.00176	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—STAR—uterine cancer	3.69e-05	0.00175	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	3.69e-05	0.00175	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—KRAS—uterine cancer	3.67e-05	0.00174	CbGpPWpGaD
Riluzole—SCN5A—Axon guidance—VEGFA—uterine cancer	3.65e-05	0.00173	CbGpPWpGaD
Riluzole—SCN5A—Axon guidance—NRAS—uterine cancer	3.61e-05	0.00171	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—NDUFB11—uterine cancer	3.57e-05	0.00169	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—SRD5A2—uterine cancer	3.57e-05	0.00169	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	3.47e-05	0.00165	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—ERBB2—uterine cancer	3.38e-05	0.00161	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—PIK3CA—uterine cancer	3.37e-05	0.0016	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—uterine cancer	3.32e-05	0.00158	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	3.27e-05	0.00155	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—TP53—uterine cancer	3.26e-05	0.00155	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—HRAS—uterine cancer	3.12e-05	0.00148	CbGpPWpGaD
Riluzole—SCN5A—Axon guidance—KRAS—uterine cancer	3.11e-05	0.00147	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—POLD1—uterine cancer	2.99e-05	0.00142	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—CTNNB1—uterine cancer	2.96e-05	0.00141	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—AKR1C1—uterine cancer	2.8e-05	0.00133	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—AKT1—uterine cancer	2.75e-05	0.00131	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—EP300—uterine cancer	2.75e-05	0.00131	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	2.71e-05	0.00129	CbGpPWpGaD
Riluzole—SCN5A—Axon guidance—HRAS—uterine cancer	2.64e-05	0.00125	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—VEGFA—uterine cancer	2.61e-05	0.00124	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—STAR—uterine cancer	2.58e-05	0.00122	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—AKR1B1—uterine cancer	2.58e-05	0.00122	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—NRAS—uterine cancer	2.57e-05	0.00122	CbGpPWpGaD
Riluzole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—uterine cancer	2.55e-05	0.00121	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	2.55e-05	0.00121	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—RRM2—uterine cancer	2.49e-05	0.00118	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—DCN—uterine cancer	2.42e-05	0.00115	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—CYP11A1—uterine cancer	2.28e-05	0.00108	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—SRD5A2—uterine cancer	2.28e-05	0.00108	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—NDUFB11—uterine cancer	2.28e-05	0.00108	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—KRAS—uterine cancer	2.22e-05	0.00105	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	2.21e-05	0.00105	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—AKR1C3—uterine cancer	2.15e-05	0.00102	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	2.09e-05	0.000991	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—POLD1—uterine cancer	2.02e-05	0.000961	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—AKR1C1—uterine cancer	1.89e-05	0.000899	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—HRAS—uterine cancer	1.88e-05	0.000894	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—RRM2—uterine cancer	1.69e-05	0.000801	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—STK11—uterine cancer	1.68e-05	0.000796	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—CYP19A1—uterine cancer	1.68e-05	0.000796	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—AKT1—uterine cancer	1.66e-05	0.000789	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—STAR—uterine cancer	1.65e-05	0.000781	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—AKR1B1—uterine cancer	1.65e-05	0.000781	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—DCN—uterine cancer	1.64e-05	0.000778	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	1.63e-05	0.000772	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—CYP11A1—uterine cancer	1.54e-05	0.000733	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—AKR1C3—uterine cancer	1.46e-05	0.000692	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—POLD1—uterine cancer	1.29e-05	0.000613	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—MTHFR—uterine cancer	1.26e-05	0.000598	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—AKR1C1—uterine cancer	1.21e-05	0.000573	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—CYP19A1—uterine cancer	1.14e-05	0.000539	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—STK11—uterine cancer	1.14e-05	0.000539	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—RRM2—uterine cancer	1.08e-05	0.000511	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.07e-05	0.000506	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—DCN—uterine cancer	1.04e-05	0.000496	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.02e-05	0.000483	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—CYP11A1—uterine cancer	9.84e-06	0.000467	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—AKR1C3—uterine cancer	9.3e-06	0.000441	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—MTHFR—uterine cancer	8.54e-06	0.000405	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	7.52e-06	0.000357	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—STK11—uterine cancer	7.24e-06	0.000344	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—CYP19A1—uterine cancer	7.24e-06	0.000344	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—PTEN—uterine cancer	7.02e-06	0.000333	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	6.8e-06	0.000323	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—EP300—uterine cancer	6.69e-06	0.000318	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	6.48e-06	0.000308	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—MTHFR—uterine cancer	5.44e-06	0.000258	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—PIK3CA—uterine cancer	4.95e-06	0.000235	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	4.8e-06	0.000228	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—PTEN—uterine cancer	4.75e-06	0.000225	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—EP300—uterine cancer	4.53e-06	0.000215	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—AKT1—uterine cancer	4.04e-06	0.000192	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—PIK3CA—uterine cancer	3.35e-06	0.000159	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—PTEN—uterine cancer	3.03e-06	0.000144	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—EP300—uterine cancer	2.89e-06	0.000137	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—AKT1—uterine cancer	2.74e-06	0.00013	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—PIK3CA—uterine cancer	2.14e-06	0.000101	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—AKT1—uterine cancer	1.75e-06	8.28e-05	CbGpPWpGaD
